Bone mineral density measurements have been criticized on the grounds that they are not a worth-while screening tool. In this paper we argue that bone mineral measurements can be an efficient diagnostic tool even if they are not of proven value for screening. There is complex relationship between the costs of a measurement, the intervention and the predictive value of the test all of which must be accounted for when assessing the value of a bone density measurement. For bone density measurements to be used for screening, a wider evaluation needs to be undertaken compared with that for their use as a diagnostic tool. We address some common objections, for example, that low compliance with screening would undermine efficiency, and show that these are not relevant.
INTRODUCTION
The debate as to the effectiveness of bone mineral density (BMO) measurements has polarized around whether they are a 'worth-while' screening tool. As such, the use of BMO measurements has been criticized on a number of grounds!,2. However, their use has recently been recommended to aid clinical decision making in osteoporosis management.'. This distinction is important because the implication in much of the literature so far has been that if a test is not worth while for screening, then it is not worth while as a diagnostic tool.
Although in some respects the information required to establish the efficiency of BMO measurements as a diagnostic tool compared with using it for screening are similar, there are a number of important differences. As a diagnostic tool for use in the management of osteoporosis, a BMO measurement may help in allocation of existing treatment regimes more efficientlyto groups of patients who are likely to receive some treatment anyway. Therefore, the question is primarily one of technical efficiency: how can we manage osteoporosis prevention or treatment better for the same or lower cost? By contrast, in screening, a BMO measurement may result in treatments being offered to women who would not previously have been considered at risk or who would not themselves have considered intervention. The question here is one of allocative efficiency-is screening and consequent intervention a good use of scarce health care The purpose of this paper is twofold: first, to consider issues affecting the efficiency of BMO measurements for diagnostic and screening purposes; and, secondly, to debate the research agenda for osteoporosis screening. In the first section of this paper we will address arguably the most important issue affecting the efficiency of BMO measurements: their ability to predict fracture risk. Following on from this we will examine the potential role BMO measurements have with respect to routine clinical management of patients with suspected osteoporosis. In the third section we shall consider a number of criticisms of a potential screening programme and which issues, in our view, should be on the screening research agenda.
PREDICTIVE VALUE OF BMD MEASUREMENTS
It has been argued that BMO measurements are not worth while for screening because of poor discrimination between fracture cases and non-fracture cases". It has been suggested that for BMO measurements to be worth while the mean BMO of those who go on to fracture compared with those who do not fracture should be separated by at least two standard deviationslI. Clearly if BMO measurements are to be used for screening or as a diagnostic aid, they need to be able to predict future fracture risk. However, the economic efficiency of BMO measurements is not constrained by the adherence to what is essentially an arbitrary statistical criterion. What is important is the interaction between the predictive value of the test, the cost of the test and the cost of any subsequent intervention. Broadly speaking, the higher the cost of the intervention the lower is the predictive value required by a test for it to be cost-effective.
ARE BMD MEASUREMENTS EFFICIENT FOR DIAGNOSTIC USE?
There have been a number of prospective and cross-sectional studies looking at the predictive value of BMD measurements. From these studies it would seem that the odds of having a fracture are approximately doubled for every standard deviation change in BMD+. In economic terms, three other pieces of information are required to judge whether such a test would be diagnostically efficient. These are: the cost of the test; the cost of the proposed intervention; and subsequent compliance with the intervention. With respect to measurement costs these have been well documented and assuming that a bone densitometer is used to maximum efficiency, then the estimated cost of a bone scan is in the region of £25 5 • However, calculating intervention costs is not quite straight forward, because although the cost of the main potential intervention, hormone replacement therapy (HRT), is readily available from published sources it varies according to the type prescribed. For instance, whilst it is usually assumed that Premarin is the treatment of choice for women with a hysterectomy a recent survey has indicated that 50% of women with a hysterectomy who are HRT users actually use the more expensive skin patch preparation of Estraderm''. Therefore, the calculation with respect to the cost effectiveness of a bone density measurement must be calculated for each form of HRT.
In the following, a calculation is undertaken assuming that the HRT to be prescribed is Prempak C. If Prempak C were prescribed in the absence of a BMD measurement, then the cost for any given unit of effectiveness would be £389 (i.e. the cost of 10 years' use). However, if Prernpak C were prescribed only to those women with a BMD measurement less/than one standard deviation (SD) below the mean then, as the relative risk of fracture is doubled, the numbers of patients requiring treatment to prevent one fracture event is halved. If treatment were directed only at those women with a BMD one standard deviation below the mean this would entail treating approximately 20% of patients. Hence, for every patient given treatment this would necessitate measuring a total of five patients at a cost of £125. This would lead to~total treatment cost of £514 for every case detected (£125+£389). For a patient whose BMD value is one SD below the mean this would lead to a halving of the numbers of patients requiring treatment to prevent one fracture and resulting in a cost per unit of effectiveness of £257 (£51412), which is less than prescribing HRT without the benefit of a BMD measurement.
The above calculation assumes 100% compliance with Prempak C by those at risk. However, compliance with any therapy is unlikely to be total. Therefore, before using a BMD measurement, we would need to know what is the minimum treatment compliance required for the measurement to be relatively cost-effective. This can be estimated as follows. A BMD measurement halves the cost per unit of effectiveness of Prernpak C (i.e. 389/2) to £195. The casedetection cost is £125. Now, dividing this by the cost per unit of effectiveness allows us to estimate the minimum required compliance for a BMD measurement to be relatively cost-effective and in this case it is 64% (i.e. £125/£195). The above calculations can be adjusted for different costs of measurement and different costs of intervention/, Hence, for example, the minimum compliance rate required for a BMD measurement when using Estraderm is 32%, and for the more expensive Estracombi only a 26% compliance rate is needed. However, for the very cheap forms of HRT, such as Premarin, the costs of a BMD measurement are likely to be greater than any avoided therapy costs.
Clearly, the above calculations can be repeated for non HRT preparations, such as etidronate (2 year cost=£299 8 , minimum compliance=83%), calcitonin (2 year cost= £944 9 , minimum compliance=26%) or vitamin D and calcium (annual cost= 103 9 , 10 year discounted treatment cost=£756, minimum compliance=33%). (For etidronate and calcitonin it is assumed a BMD measurement is repeated every 2 years to monitor treatment, whilst for vitamin D and calcium it is assumed that only one measurement is performed at age 75 with an average of 10 years of treatment thereafter.)
Given that BMD measurements appear, in some circumstances, to be an efficient use of. resources for diagnostic purposes can they also be used efficiently in population screening? In the following section we will highlight areas of controversy and our suggestions as to the issues that should be on the osteoprosis screening research agenda.
SCREENING
The dominant cost of an osteoporosis screening programme is likely to be the intervention 2 . In contrast to BMD measurements for case-finding or diagnostic purposes, screening will involve giving an intervention to women who would be unlikely to have previously taken any therapy. Therefore, a wider evaluation should be undertaken before a screening programme can be justified. Despite this a number of criticisms of BMD screening have been made which do not necessarily relate to the efficiency of a screening programme. These objections need to be addressed so that the research agenda moves to more valuable areas.
Objection 1: compliance with screening will be poor This objection was raised by the first Fffective Health Care bulletin". This issue is only relevant if non-attenders to screening are either at higher risk of the target disease or non-attendance increases costs10. With respect to osteoporosis screening non-attenders seem to have higher bone densityl ' and with the appropriate recruitment method nonattendance will not increase costs!", Therefore, low compliance is unlikely to affect the efficiency of a screening programme.
Objection 2: screening will prevent only a small number of fractures
This objection has been raised several times l ,2. However, in economic terms the actual proportion of fractures prevented is only relevant when set against costs. A number of studies have shown that trying to increase the volume of cases detected, and hence disease averted, increases costslO, 13,14. Hence, by attempting to increase the numbers of fractures averted through such methods as improving compliance a high marginal cost per averted fracture might result. In contrast, preventing only a small number of fractures may be done at a relatively low cost per averted fracture and thus be more efficient. For example, it has been shown, in the field of breast cancer screening, that increasing the proportion of preventable cancers from 76% to 86% is associated with more than a doubling of screening costs!". Hence, preventing a smaller proportion of cancers, or fractures, may be more cost effective than attempting to prevent as many as possible.
Ojection 3: screening will not save money
It has been argued that osteoporosis screening will not save the NHS money", Screening like other forms of health care is not about saving money, it is about improving health. Clearly if a screening programme saves money then it should almost always be undertaken. However, the reverse is not true. What is important is the cost per unit of health gain.
Objection 4: BMD measurements predict fracture risk poorly
In our view the efficiency of a test should be dependent upon the test's costs and the possible side-effects of the test, not upon arbitrary statistical criteria 1,2. For example, screening for Down syndrome can involve two tests: the triple test and amniocentesis (or chorionic villus sampling). If a test were defined as a good test merely on its predictive ability then an amniocentesis would be a good test and the triple test a poor one. However, the negative effects of an amniocentesis are high. The test is unpleasant for the mother and can be dangerous to the fetus. Hence, because of these effects, amniocentesis is not routinely offered to all pregnant women. In contrast, the triple test which has a sensitivity of only 66% (similar to BMD measurements) is low cost when compared to amniocentesis and, whilst pregnancy termination could not be considered on this test alone, it is of sufficiently low cost to be an efficient test'>, Therefore, in this example, the low-cost, low-effectiveness test is used for mass screening whilst the high-cost, highly effective test is reserved for high risk sub-groups. With respect to BMO measurements, in economic terms their predictive value must be assessed together with the cost of measurement and the cost of any proposed subsequent intervention.
Objection 5: preventive measures for the entire population will be more effective 1
It is often advocated that osteoporosis preventive measures should be directed at the entire population and not just those at highest risk!,2. However, evidence as to the effectiveness or efficiency of such a strategy has not been demonstrated. To our knowledge the population approach to prevention has not been tested and the strategy may not be effective let alone cost-effective.
Research issue 1: effectiveness and timing of intervention
HRT is generally seen as the intervention of choice for prevention of osteoporosis. Case-control studies are agreed it is effective in preventing hip fractures in relatively young women, but its effectiveness amongst older women may not be as markedl''. Whilst attention in the osteoporosis field is quite rightly focused upon hip fracture there are other fracture events to consider, such as the steep rise in perimenopausal Colles' fractures! 7. Given that BMO measurements predict perimenopausal fractures it might be fruitful to examine, in a randomized fashion, the potential of a screening programme to reduce the perimenopausal fracture incidence 18 . 19 . A key issue affecting the economics of HRT and hip fractures, with or without screening, is the delay between intervention, at the age of SO, and the potential benefit occurring some 20 to 30 years later. This is because of the process of discounting. As society generally prefers benefits to accrue within the present time period, discounting gives more weight to health and other benefits occurring now compared with those in the future. Therefore, given the large delay of any hip fracture benefits accruing to a perimenopausal screening programme these are heavily discounted. Therefore, in economic terms a promising approach would be to try to intervene closer in time to the fracture event. Recent epidemiological modelling exercises suggest that intervening in older postmenopausal women may be nearly as effective as intervening soon after menopause/". Therefore, rather than attempting to screen and intervene amongst perimenopausal women it might be better to screen and treat women aged 65 or 70. Indeed, a recent economic evaluation of HRT has shown that it is likely to be more cost effective ifgiven to women aged 65, for life, than giving it to women aged 50 for 15 years-".
Research issue 2: alternatives to HRT
Recent evidence suggests that vitamin 0 and calcium supplementation amongst the elderly reduces the incidence of fracture 22 . However, pharmacological preparations of calcium are expensive". Therefore, a strategy of using vitamin 0, calcium and screening might be relatively costeffective. Such a comparison could be made through economic modelling techniques; indeed, such an economic model indicates that HRT is a more cost-effective strategy than a lifestyle regime of increasing exercise and calcium consumption.". Furthermore, another economic analysis suggests that targeting vitamin 0 and calcium towards the highest risk groups in the elderly might reduce the number of hip fractures at a reasonable cost",
Research issue 3: other effects of screening
Any screening service may have detrimental effects such as causing anxiety amongst those labelled at high risk. In contrast, screening may provide reassurance to those not at risk. Such issues need to be assessed in any evaluation of screening.
Research issue 4: population strategies
Whilst this issue is not strictly within the remit of this paper it needs to be considered within an economic evaluation as being a potential alternative. Randomized trials of interventions directed in a population setting should be undertaken to assess whether they are reasonable alternatives to or complement the high risk approach.
DISCUSSION
In this paper we have shown that BMD measurements can be relatively cost-effective when used within a case-finding setting. This is important given that the prevention of osteoporosis is receiving increased attention both in the lay and medical press, perhaps influencing GPs to the extent that over 60% would consider prescribing HRT for its prevention/". Contemporaneously with this increased interest, drug manufacturers are actively promoting transdermal forms of HRT. The cost of these new, transdermal, forms of HRT are substantially greater than that of the older oral varieties. For example, we estimate that 10 years of Premarin would cost approximately £ 194 whereas its transdermal equivalent, Estraderm, would cost £788. Combined transdermal preparations are even more expensive. Despite no evidence that transdermal preparations are any more effective than their oral equivalents at preventing bone loss or reducing menopausal symptoms 24 ,25, we have noted that about 50% of women with a hysterectomy taking HRT are using transdermal preparations", Ideally, if a GP is considering prescribing HRT for the prevention of osteoporosis then the cheapest preparation which is associated with bone loss prevention should be considered. In the unlikely event that GPs and other clinicians were prevented from prescribing the more expensive HRT preparations (for example, by enforcement of a limited list), then a key benefit of a bone scan, of cost savings by targeting expensive treatment, would be reduced. Furthermore, if a patient clearly is anxious to take HRT long term no matter what result of a bone scan, then having a measurement only adds to the total cost of treatment. However, clinical decision making is rarely so simple. Even if a clinician was restricted to prescribing Premarin, scanning still might be appropriate. Thus, although a bone scan plus Premarin increases the cost per unit of effectiveness from £ 194 to £222 this extra cost might still be justified if there were extra benefits. For example, a clinician might be reluctant to prescribe HRT to a woman with a family history of breast cancer if she was not at substantially increased risk of osteoporosis. Furthermore, if a patient is anxious about developing osteoporosis, but is reluctant to take HRT unless she is at relatively high risk, then a high bone scan result may give sufficient reassurance for her to avoid taking HRT. Clearly, such reassurance is a health care benefit even if it cannot be given a monetary value. Alternatively, the dosage of other therapies, such as steroids, might be adjusted in the light of a bone scan result.
As for using BMD measurements in a mass population screening programme we support the view that more research is needed before such a programme can be implemented''. However, this research should be directed at issues that will affect the potential efficiency of a screening programme.
In summary, purchasing a BMD measurement is likely to be cost-effective if the question the clinician seeks to answer is one of technical efficiency. In contrast, BMD measurement as a mass screening tool still requires further evaluation before it can be recommended on economic grounds.
